As the legendary investor Warren Buffett once said, forecasts about the future usually tell you more about the forecaster than they do about the future.
With the pharma industry putting the ‘blockbuster’ age behind it and moving into meeting needs across myriad niche disease areas, what is the impact and therefore change of requirement in terms of
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.